# Ruth Ladenstein

Source: https://onco.cc/people/ruth-ladenstein/  
OnCo record `ruth-ladenstein` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Chaired the SIOPEN HR-NBL1 trial, the largest neuroblastoma trial ever, which set European standards for high-risk disease.

## Summary

Ruth Ladenstein (Vienna) chaired SIOPEN HR-NBL1, the 3,000-patient trial that established busulfan-melphalan as the preferred myeloablative regimen for high-risk neuroblastoma and showed that adding interleukin-2 to dinutuximab beta immunotherapy adds toxicity without benefit. She has led SIOP Europe and coordinates the European neuroblastoma research network.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: paediatric; neuroblastoma; cooperative-group
- Role: Professor of Paediatrics, St. Anna Children's Hospital and Children's Cancer Research Institute, Vienna
- Specialisms: Neuroblastoma; High-dose chemotherapy; European paediatric trials; Immunotherapy

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Ladenstein%20R%5BAuthor%5D%20neuroblastoma

## Connected records

- cancers: [Neuroblastoma (paediatric)](https://onco.cc/cancers/neuroblastoma/)
- institutions: [St. Anna Children's Hospital and Children's Cancer Research Institute (CCRI)](https://onco.cc/institutions/st-anna-ccri-vienna/)
- trials: [SIOPEN HR-NBL1](https://onco.cc/trials/hr-nbl1/)

---
JSON: https://onco.cc/api/v1/entities/ruth-ladenstein.json